ACAD
38.17
+0.26
+0.69%
AEMD
7.05
-0.1
-1.40%
APRI
1.35
+0.12
+9.76%
ARNA
2.71
+0.06
+2.26%
ATEC
0.54
-0.03
-5.26%
CNAT
4.05
+0.37
+10.05%
CRXM
0.37
-0.02
-5.13%
CYTX
0.315
+0.016
+5.246%
DXCM
94.19
+0.45
+0.48%
GNMK
10.02
+0.59
+6.26%
HALO
18.41
+0.37
+2.05%
ILMN
201.7
-0.24
-0.12%
INNV
0.148
+0.003
+2.069%
INO
7.73
+0.75
+10.74%
ISCO
3.98
+0.33
+9.04%
ISIS
51.54
-0.02
-0.04%
LGND
95.04
+0.79
+0.84%
LPTN
0.225
+0.015
+7.092%
MBVX
1.685
-0.005
-0.296%
MEIP
1.73
+0.04
+2.37%
MNOV
2.94
-0.03
-1.01%
MRTX
26.66
+1.17
+4.59%
MSTX
0.47
+0.02
+3.96%
NBIX
46.67
+0.41
+0.89%
NUVA
53.75
+1
+1.90%
ONCS
5.2
+0.02
+0.48%
ONVO
2.54
+0.04
+1.60%
OREX
2.89
+0.13
+4.71%
OTIC
23.5
+0.12
+0.51%
QDEL
20.45
-0.25
-1.21%
RCPT
231.96
0.00
0.00%
RGLS
8.27
+0.79
+10.56%
RMD
52.47
+0.82
+1.59%
SCIE
0.015
+0.001
+3.5714%
SPHS
0.89
+0.03
+3.49%
SRNE
13.65
+0.33
+2.48%
TROV
6.33
+0.55
+9.52%
VICL
0.59
+0.03
+5.32%
VOLC
18
0.00
0.00%
ZGNX
18.41
+1.35
+7.91%
ACAD
38.17
+0.26
+0.69%
AEMD
7.05
-0.1
-1.40%
APRI
1.35
+0.12
+9.76%
ARNA
2.71
+0.06
+2.26%
ATEC
0.54
-0.03
-5.26%
CNAT
4.05
+0.37
+10.05%
CRXM
0.37
-0.02
-5.13%
CYTX
0.315
+0.016
+5.246%
DXCM
94.19
+0.45
+0.48%
GNMK
10.02
+0.59
+6.26%
HALO
18.41
+0.37
+2.05%
ILMN
201.7
-0.24
-0.12%
INNV
0.148
+0.003
+2.069%
INO
7.73
+0.75
+10.74%
ISCO
3.98
+0.33
+9.04%
ISIS
51.54
-0.02
-0.04%
LGND
95.04
+0.79
+0.84%
LPTN
0.225
+0.015
+7.092%
MBVX
1.685
-0.005
-0.296%
MEIP
1.73
+0.04
+2.37%
MNOV
2.94
-0.03
-1.01%
MRTX
26.66
+1.17
+4.59%
MSTX
0.47
+0.02
+3.96%
NBIX
46.67
+0.41
+0.89%
NUVA
53.75
+1
+1.90%
ONCS
5.2
+0.02
+0.48%
ONVO
2.54
+0.04
+1.60%
OREX
2.89
+0.13
+4.71%
OTIC
23.5
+0.12
+0.51%
QDEL
20.45
-0.25
-1.21%
RCPT
231.96
0.00
0.00%
RGLS
8.27
+0.79
+10.56%
RMD
52.47
+0.82
+1.59%
SCIE
0.015
+0.001
+3.5714%
SPHS
0.89
+0.03
+3.49%
SRNE
13.65
+0.33
+2.48%
TROV
6.33
+0.55
+9.52%
VICL
0.59
+0.03
+5.32%
VOLC
18
0.00
0.00%
ZGNX
18.41
+1.35
+7.91%
Home » Archive by Category

Syndication

GCMS Operator (Carmel Mountain)

August 27, 2015 – 10:31 am

JOB SUMMARY:
This position is responsible for assigned Technical Operations of the Forensic Toxicology Laboratory. The position reports to the Laboratory Manager.
PRINCIPLE ACTIVITIES AND RESPONSIBILITIES
1. Operate and maintain GCMS analyzers.
2 […

Manufacturing Technician (Sorrento Mesa)

August 27, 2015 – 10:21 am

Technicians are responsible for conducting GMP manufacturing of solid oral and liquid oral pharmaceutical dosage forms for Phase I and Phase II clinical trials.
The hours and shifts of this position may vary in order to meet the needs of the product […

Manufacturing Technician – solutions, medical device assembly (Carlsbad)

August 27, 2015 – 9:52 am

Manufacturing Technician – solutions, medical device assembly, Carlsbad, CA
Kelly Scientific Resources, a division of Kelly Services, is currently seeking experienced Manufacturing Technicians with basic laboratory and medical device assembly experi […

MEPS Real-Time, Inc. Announces Contract With Yankee Alliance for Intelliguard Kit and Tray Management System RFID Smart Tags

August 27, 2015 – 9:15 am

CARLSBAD, CA–(Marketwired – Aug 27, 2015) – MEPS Real-Time, Inc., developer of Intelliguard® RFID Solutions for pharmacy automation and medication inventory management, today announced a new supply chain partner agreement for Intelliguard® Kit and Tray Management RFID Smart Tags with Yankee Alliance. 

Portfolio & Operations Coordinator, Oncology Research Unit – Pfizer Inc. – La Jolla, CA

August 27, 2015 – 8:13 am

Experience in a biotechnology or pharmaceutical company highly preferred. Org Marketing Statement….
From DeviceSpace.com – 27 Aug 2015 15:13:56 GMT
– View all La Jolla jobs

QA Document Control Manager – HUYA Bioscience International – San Diego, CA

August 27, 2015 – 8:13 am

Applicant must have a minimum of 5-7 years of experience with a focus on Quality Assurance in the Biotechnology and/or Pharmaceutical Industry….
From DeviceSpace.com – 27 Aug 2015 15:13:38 GMT
– View all San Diego jobs

Parks Associates: 25% of U.S. Broadband Households Are Interested in Reviewing Doctors’ Notes Through a Health Portal

August 27, 2015 – 6:00 am

Market Research Firm Hosts Second-Annual Connected Health Summit, September 9-10 in San Diego

HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting

August 27, 2015 – 5:02 am

SAN DIEGO, Aug. 27, 2015 /PRNewswire/ — HUYA Bioscience International (HUYA) today announced the sponsorship of the second annual meeting of the Japan Society of HTLV-1, held this week at the University of Tokyo Medical Science Institute Auditorium. The purpose of the Society is to promote research on HTLV-1 and HTLV-1-associated diseases, as well as the development of medical technology and research related to these fields to advance science, the national health and welfare.

“HUYA is proud to support this prestigious conference,” said Mireille Gillings, Ph.D., CEO of HUYA. “We are actively developing our novel oral HDAC inhibitor with immunomodulatory properties, HBI-8000, for lymphomas in Japan, including Adult T-cell Lymphoma/Leukemia (ATL), which is caused by HTLV-1 infection.”

“I have been delighted to help HUYA over the years define the development path for HBI-8000 as a promising therapy for lymphomas in Japan,” said Toshiki Watanabe, M.D., Ph.D., the President of the Japan Society of HTLV-1, and Professor and Chairman, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, the University of Tokyo.

HBI-8000 is currently in a Phase 1 clinical trial in Japan in patients with non-Hodgkin’s lymphoma, including ATL patients, following the acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of HUYA’s accelerated development strategy in Japan. The initiation of clinical trials of HBI-8000 in Japan followed the recent approval of the drug by the Chinese Food and Drug Administration for relapsed or refractory peripheral T-cell lymphoma; in China, the drug is marketed as Epidaza by Shenzhen Chipscreen Biosciences. The clinical development of HBI-8000 in Japan leverages clinical data from Chinese clinical trials through the Tripartite Cooperation on Health between China, South Korea and Japan.

About Lymphoma and HTLV-1

Lymphoma is the most common blood cancer. The two main forms of lymphomas are Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL). Lymphoma occurs when cells of the immune system called lymphocytes, a type of white blood cell, grow and multiply uncontrollably. There are approximately 138,000 cases and 53,000 non-Hodgkin’s lymphoma (NHL) deaths per year in the United States and Europe. NHL is the seventh most commonly diagnosed cancer in both men and women in the United States. The lowest NHL rates are found in eastern and south central Asia (2 to 3 per 100,000 population). Peripheral T-cell lymphoma (PTCL) consists of a group of rare and usually aggressive NHLs that develop from mature T-cells. Most T-cell lymphomas are PTCLs, which collectively account for about 10 to 15 percent of all NHL cases in the U.S. In Japan, the rate of PTCL is estimated at 2-3 patients/100,000 population. The most common form of T-cell lymphoma in Japan is Adult T-cell Lymphoma/Leukemia (ATL) caused by HTLV-1 infections. ATL accounts for about 30 percent of all T-cell lymphomas in Japan. ATL is a disease of high unmet medical need in Japan where it is responsible for approximately 1,000 deaths per year. HTLV-1, the virus that causes ATL, has a high prevalence in Japan with more than 1 million people infected. Worldwide, HTLV-1 infects an estimated 10 million or more, and is endemic in countries including the Caribbean islands and certain regions of Africa, Central and South America and the Middle East.

About HBI-8000

HBI-8000 is a member of the benzamide class of histone deacetylase (HDAC) inhibitors designed to block the catalytic pocket of Class I HDACs. HBI-8000 is an orally bioavailable, low-nanomolar inhibitor of cancer-associated HDAC enzymes with favorable pharmacology and safety profiles. HBI-8000 inhibits cancer-associated Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10 at nanomolar concentrations and stimulates accumulation of acetylated histones H3 and H4 in tumor cells. Studies with human-derived tumor cell lines have demonstrated that HBI-8000 inhibits the growth of many tumor cell lines via multiple mechanisms of action, including epigenetic regulation of tumor cell growth and apoptosis, immunomodulatory effects such as activation of NK- and CD8 T-cell-mediated antitumor activity, as well as repression of genes associated with drug resistance. To date, HBI-8000 has been dosed in various types of hematological and solid tumors in several clinical trials, including a Phase 1 trial completed in the United States.

About HUYA Bioscience International

HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. Earlier this year, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards. www.huyabio.com

Contact details:
Yiota Merianos
HUYA Corporate Communications
+1.858.353.1217
ymerianos@huyabio.com

 

SOURCE HUYA Bioscience International

Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer

August 27, 2015 – 5:00 am

Experienced Oncology Leader To Spearhead Clinical Development Of CytomX Probody(TM) Therapeutic Pipeline

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2015 /PRNewswire/ — CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced that Rachel Humphrey, M.D., previously a member of the company’s Board of Directors, has been appointed chief medical officer. Dr. Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca, and also oversaw clinical development of Yervoy® (ipilmumab), the first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb and the development of Nexavar (sorafenib) at Bayer. 

“Since joining the CytomX board of directors in March, I have been able to see at first-hand the tremendous power of the Probody platform,” said Dr. Humphrey. “I am excited to now be joining the management team to help build a great company that has the potential to make a real difference for patients.”

Added Sean McCarthy, D. Phil., chief executive officer of CytomX, “We were thrilled to have Rachel join the Board earlier this year, and having her now transition to the management team will allow us to benefit even more from her decades of experience in successful oncology product development and registration. Rachel’s recruitment is a reflection of how we continue to execute towards our vision of transforming lives with safer, more effective therapies.”

Dr. Humphrey recently held positions as vice president and head of immuno-oncology at Eli Lilly and at AstraZeneca, where she was responsible for building the immuno-oncology departments and supervising the strategies and designs for all the immuno-oncology agents in development. She previously served as vice president of product development at Bristol-Myers Squibb, where she led all aspects of the clinical development of Yervoy through the submission of global biologics license applications and global launch. At Bayer, Dr. Humphrey supervised the early and late stage clinical development of Nexavar for treatment of renal cell carcinoma. She began her career as an oncology fellow and staff physician at the National Cancer Institute. Dr. Humphrey trained in internal medicine at the Johns Hopkins Hospital, received her medical degree from Case Western Reserve University and her bachelor’s degree from Harvard University.  

In connection with her appointment as chief medical officer, Dr. Humphrey will resign from the Board of Directors of CytomX.

About CytomX Therapeutics, Inc.

CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on its Probody technology platform. The company uses the platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class cancer therapeutics against novel targets. CytomX believes that its Probody platform will improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, such as CD-166, that are difficult to drug and lead to damage to healthy tissues, or toxicities. In addition to its proprietary programs, CytomX is collaborating with strategic partners including Bristol-Myers Squibb Company, Pfizer Inc. and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Media Contacts:
Canale Communications
Ian Stone
ian@canalecomm.com 
619-849-5388

Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com 
646-378-2973

 

SOURCE CytomX Therapeutics

Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease

August 27, 2015 – 4:30 am

CHICAGO and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2015 /PRNewswire/ — The Pulmonary Fibrosis Foundation (PFF) and Veracyte, Inc. (NASDAQ: VCYT) announced that the organizations are partnering on a U.S. patient survey to advance understanding of patients’ diagnostic experiences with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). The Interstitial Lung Disease Patient Journey (INTENSITY) survey will assess the steps and time required for patients to receive a diagnosis, specific obstacles hindering timely diagnosis, and the physical and emotional impact of patients’ diagnostic journey.

“IPF and other ILDs are notoriously difficult to diagnose, leading to treatment delays, added healthcare costs and significant emotional impact for patients and caregivers,” said Gregory P. Cosgrove, MD, chief medical officer of the PFF. “Results from the INTENSITY survey will help us more fully understand patients’ diagnostic experiences so that we can further our efforts among all stakeholders to improve timely diagnosis and treatment of this disease. This ability is more critical than ever, given the recent availability of treatments that can slow progression of IPF.”

Dr. David Lederer, PFF senior medical advisor, education and awareness, led development of the INTENSITY survey, which is being conducted online by independent healthcare research organization Outcomes Insights, with funding support from Veracyte. Results are expected to be announced later this year.

“We are delighted to be partnering with the Pulmonary Fibrosis Foundation, the leading pulmonary fibrosis information resource and support network in the United States, on this important survey,” said Bonnie Anderson, Veracyte’s president and chief executive officer. “This effort demonstrates our commitment to address the significant needs of ILD and IPF patients.”

About Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a condition in which, over a period of time, lung tissue becomes thickened, stiff and scarred. The development of the scar tissue is called fibrosis. As the lung tissue becomes scarred and grows thicker, the lungs lose their ability to transfer oxygen into the bloodstream. As a result, the brain and other organs don’t receive enough oxygen. In some cases, doctors can determine the cause of the fibrosis, but in many cases, there is no known cause. When the cause of the fibrosis is unknown (and certain pathologic or radiographic criteria are met), the disease is called idiopathic pulmonary fibrosis, or IPF. There is no cure for IPF. Presently, there are two FDA-approved treatments for IPF in the United States. IPF is the most common and most deadly form of interstitial lung disease (ILD), a diagnostic category comprising more than 200 diverse lung disorders characterized by progressive scarring of the lungs.

About the Pulmonary Fibrosis Foundation

The mission of the Pulmonary Fibrosis Foundation (PFF) is to serve as the trusted resource for the pulmonary fibrosis (PF) community by raising awareness, providing disease education, advancing care and funding research. The PFF collaborates with physicians, organizations, people with PF and caregivers worldwide. The Pulmonary Fibrosis Foundation has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The PFF Summit 2015: From Bench to Bedside, its third biennial international health care conference, will be held November 12-14, 2015 in Washington, D.C. For more information visit www.pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733) or +1 312.587.9272 from outside of the U.S.

About Veracyte

Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s Afirma® Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for approximately 150 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. Veracyte is developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

For the Pulmonary Fibrosis Foundation:

Media:

Michelle Michael

Vice President, Marketing and Communications

312.239.6628

mmichael@pulmonaryfibrosis.org 

For Veracyte:

Media:

Tracy Morris 

Michele Parisi

650-380-4413 

925-864-5028

tracy.morris@veracyte.com 

mparisi@forwardhealthinc.com

Investors:

Pam Lord 

Canale Communications

619-849-6003

pam@canalecomm.com

 

SOURCE Veracyte